Atypical Antipsychotic Use Among Medicaid-Insured Children and Adolescents: Duration, Safety, and Monitoring Implications

Change in metabolic parameters and weight in response to risperidone monotherapy in young children with nonpsychotic disorders: a prospective open-label study

(2013) Burcu Ersoz Alan et al.   Child and Adolescent Mental Health

National Trends in the Office-Based Treatment of Children, Adolescents, and Adults With Antipsychotics

(2012) Mark Olfson et al.   ARCHIVES OF GENERAL PSYCHIATRY

Metabolic Screening in Children Receiving Antipsychotic Drug Treatment

(2012) Elaine H. Morrato et al.   ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE

The Relationship between Mental Health Diagnosis and Treatment with Second-Generation Antipsychotics over Time: A National Study of U.S. Medicaid-Enrolled Children

(2012) Meredith Matone et al.   HEALTH SERVICES RESEARCH

Adverse Effects of Second-Generation Antipsychotics in Children and Adolescents

(2012) David Cohen et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Concurrent Mental Health Therapy Among Medicaid-Enrolled Youths Starting Antipsychotic Medications

(2012) Emily Harris et al.   PSYCHIATRIC SERVICES

Antipsychotic Use by Medicaid-Insured Youths: Impact of Eligibility and Psychiatric Diagnosis Across a Decade

(2012) Julie Magno Zito et al.   PSYCHIATRIC SERVICES

A prospective open-label trial of quetiapine monotherapy in preschool and school age children with bipolar spectrum disorder

(2011) Gagan Joshi et al.   JOURNAL OF AFFECTIVE DISORDERS

Early Diagnoses and Psychotherapeutic Medication Treatment Experiences of a Cohort of Children Under 6 Years Old Who Received Antipsychotic Treatment in Florida's Medicaid Program

(2011) Robert J. Constantine et al.   JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY

Trends in Antipsychotic Drug Use by Very Young, Privately Insured Children

(2011) Mark Olfson et al.   JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY

Antipsychotic Medication Use Among Children and Risk of Diabetes Mellitus

(2011) S. E. Andrade et al.   PEDIATRICS

Antipsychotic Treatment Among Youth in Foster Care

(2011) S. dosReis et al.   PEDIATRICS

Exposure to antipsychotic medications over a 4-year period among children who initiated antipsychotic treatment before their sixth birthday

(2011) Robert J. Constantine et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Metabolic Testing Rates in 3 State Medicaid Programs After FDA Warnings and ADA/APA Recommendations for Second-Generation Antipsychotic Drugs

(2010) Elaine H. Morrato et al.   ARCHIVES OF GENERAL PSYCHIATRY

Antipsychotic polypharmacy in the treatment of children and adolescents in the fee-for-service component of a large state medicaid program

(2010) Robert J. Constantine et al.   CLINICAL THERAPEUTICS

Broadened Use Of Atypical Antipsychotics: Safety, Effectiveness, And Policy Challenges

(2009) Stephen Crystal et al.   HEALTH AFFAIRS

Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents

(2009) Christoph U. Correll   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Implications of Marked Weight Gain Associated With Atypical Antipsychotic Medications in Children and Adolescents

(2009) Christopher K. Varley   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Weight Gain and Metabolic Abnormalities During Extended Risperidone Treatment in Children and Adolescents

(2009) Chadi A. Calarge et al.   JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY

Practice Parameter on the Use of Psychotropic Medication in Children and Adolescents

(2009) John Walkup   JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY

Metabolic and Cardiovascular Adverse Events Associated With Antipsychotic Treatment in Children and Adolescents

(2008) Roger S. McIntyre et al.   ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE